Kamada Ltd. stock is up 25.64% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36.36% of the previous 10 December’s closed higher than November. 100% of analysts rate it a buy.
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to AATD. It also provides Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity.